FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Rite Aid (NYSE:US90274J5618=UBSS), the struggling U.S. pharmacy chain, has agreed to sell pharmacy assets from over 1,000 store locations as part of its ongoing bankruptcy proceedings. Buyers include major retailers like CVS Pharmacy, Walgreens, Kroger (NYSE:KR), Albertsons (NYSE:ACI), and Giant Eagle.
CVS will acquire and operate many Rite Aid and Bartell Drugs stores across Washington, Oregon, and Idaho, according to a recent filing. Despite the asset sales, Rite Aid emphasized that stores will remain open and customers can continue accessing prescription refills, vaccinations, and other pharmacy services without disruption.
The sale primarily involves prescription files and related assets. While Walgreens declined to comment, the other companies involved have yet to issue statements.
This marks Rite Aid’s second bankruptcy filing in under two years, driven by weak retail performance, mounting debt exceeding $2 billion, and ongoing cash flow issues. The Pennsylvania-based company has already received court approval to fast-track the sale of its pharmacy business, with a final approval hearing scheduled for May 21. All transactions are still subject to regulatory approval.
Rite Aid CEO Matt Schroeder said the company aims to ensure a seamless transition for pharmacy customers while minimizing job losses. “These agreements ensure our pharmacy customers will experience a smooth transition while preserving jobs for some of our valued team members,” Schroeder noted.
The move signals a major shift in the U.S. retail pharmacy landscape, as industry giants like CVS and Kroger strengthen their market positions by absorbing Rite Aid’s assets. This development comes as pharmacy chains across the country navigate rising competition, tighter margins, and shifting consumer behavior.
The outcome of the May 21 court hearing will be critical in shaping the next chapter for Rite Aid and its employees.
